Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Several studies have demonstrated that the major cause for doxorubicin resistance in osteosarcoma is the increased expression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp).
|
30430199 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The levels of ROR, miR-153-3p, and ABCB1 in cisplatin-resistant OS tissues and cells were detected by qRT-PCR and/or Western blot assay.
|
31539112 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells.
|
30204936 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HA-Lsdox showed favorable drug-release profile and higher toxicity in vitro and in vivo than dox or the FDA-approved liposomal dox Caelyx<sup>®</sup> against Pgp-overexpressing osteosarcoma, displaying the same cardiotoxicity profile of Caelyx<sup>®</sup>.
|
31047947 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study determined if pioglitazone (PIO), a PPARγ agonist, could modulate P-gp and overcome doxorubicin (DOX)-resistance in a patient-derived orthotopic xenograft (PDOX) model of osteosarcoma.
|
31545293 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, RA is a promising potential therapeutic for the treatment of doxorubicin resistance in OS.
|
30745853 |
2019 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulating the expression of P-gp in OS maybe a promising strategy to overcome cisplatin resistance.
|
30952710 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of doxorubicin-resistance is the main difficulty for osteosarcoma treatment.
|
30974157 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the results indicated that SNHG12 mediated doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis.
|
30119255 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was identified that VASH1 was able to inhibit drug resistance in osteosarcoma cells through regulation of P-gp via the AKT signal pathway.
|
29556314 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, our results elucidated for the first time that TIPE2 sensitizes osteosarcoma cells to cis-platin through downregulation of MDR1 and may be a novel target in osteosarcoma therapy.
|
30114619 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, it was concluded that LIMK1 serves a key role in the MDR of osteosarcoma and functions through MDR1.
|
29387219 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, results indicate the vital role of LUCAT1 in the methotrexate resistance regulation through miR-200c/ABCB1 pathway, providing a novel insight and treatment strategy for osteosarcoma drug resistance.
|
29170124 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a previous study, we reported a novel lncRNA, ODRUL, that could promote doxorubicin resistance in OS.
|
28750740 |
2017 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, based on our previous study, we further identified that the lncRNA FOXC2-AS1 and its antisense transcript FOXC2 are positively up-regulated in doxorubicin-resistant osteosarcoma cell lines and tissues, correlate with poor prognosis and promote doxorubicin resistance in osteosarcoma cells in vitro and in vivo.
|
28323030 |
2017 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells.
|
28693150 |
2017 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Together, our study demonstrated that lncRNA FENDRR may act as an inhibitory molecule of doxorubicin-resistance through down-regulating the expression of ABCB1 and ABCC1 genes in osteosarcoma cells.
|
29069754 |
2017 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
|
27486760 |
2016 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we assessed the expression of P-gp after suppressing ASS1 in Dox-sensitive cells (MCF-7 and KHOS) and after transfecting ASS1 into Dox-resistant cells (ES-X, VAESBJ, ASPS-KY and KHOSR2).
|
27683125 |
2016 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
|
27222034 |
2016 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that multidrug resistant osteosarcoma cells are able to spread their ability to resist the effects of doxorubicin treatment on sensitive cells by transferring exosomes carrying MDR-1 mRNA and its product P-glycoprotein.
|
27176642 |
2016 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, we concluded that lncRNA ODRUL may act as a pro-doxorubicin-resistant molecule through inducing the expression of the classical multidrug resistance-related ABCB1 gene in osteosarcoma cells .These findings may provide a novel target for reversing doxorubicin resistance in OS.
|
26408180 |
2016 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Then we adopted the CRISPR-Cas9, a robust and highly efficient novel genome editing tool, to determine its effect on reversing drug resistance by targeting endogenous ABCB1 gene at the DNA level in osteosarcoma MDR cell lines.
|
27835872 |
2016 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
|
25727016 |
2015 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, icariin possesses a reversal effect on multidrug resistance in MG-63/DOX cells through down-regulation of the MDR1 and the PI3K/Akt pathway, and has the potential to be an adjunct to chemotherapy for osteosarcoma.
|
25747987 |
2015 |